Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) FCF Margin (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed FCF Margin for 15 consecutive years, with 13.0% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin rose 895.0% to 13.0% in Q3 2025 year-over-year; TTM through Sep 2025 was 2.61%, a 473.0% increase, with the full-year FY2024 number at 3.44%, down 1876.0% from a year prior.
  • FCF Margin was 13.0% for Q3 2025 at Gyre Therapeutics, up from 6.73% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 41.67% in Q4 2022 to a low of 1777.65% in Q2 2021.
  • A 5-year average of 385.44% and a median of 3.82% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: plummeted -163089bps in 2021, then skyrocketed 155243bps in 2023.
  • Gyre Therapeutics' FCF Margin stood at 735.89% in 2021, then soared by 106bps to 41.67% in 2022, then tumbled by -91bps to 3.82% in 2023, then tumbled by -359bps to 9.9% in 2024, then soared by 231bps to 13.0% in 2025.
  • Per Business Quant, the three most recent readings for GYRE's FCF Margin are 13.0% (Q3 2025), 6.73% (Q2 2025), and 1.01% (Q1 2025).